Literature DB >> 32926353

Bulevirtide: First Approval.

Connie Kang1, Yahiya Y Syed2.   

Abstract

Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32926353     DOI： 10.1007/s40265-020-01400-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  27 in total

Review 1.  Entry Inhibitors of Hepatitis B and D Viruses.

Authors:  Yang Yang; Youhua Xie
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.

Authors:  Yi-Wen Huang; Albert Qin; Chan-Yen Tsai; Pei-Jer Chen
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 3.  Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Giacomo Emanuele Maria Rizzo; Giuseppe Cabibbo; Antonio Craxì
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

Review 4.  Antimicrobial peptides and their potential application in antiviral coating agents.

Authors:  Emanuelle D Freitas; Rogério A Bataglioli; Josephine Oshodi; Marisa M Beppu
Journal:  Colloids Surf B Biointerfaces       Date:  2022-07-08       Impact factor: 5.999

5.  AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis.

Authors:  Sheila Maestro; Nahia Gómez-Echarte; Gracián Camps; Carla Usai; Lester Suárez; África Vales; Cristina Olagüe; Rafael Aldabe; Gloria González-Aseguinolaza
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 6.  HDV Pathogenesis: Unravelling Ariadne's Thread.

Authors:  Eirini D Tseligka; Sophie Clément; Francesco Negro
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

7.  Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

Authors:  Hsien-Hong Lin; Shih-Jer Hsu; Sheng-Nan Lu; Wan-Long Chuang; Chao-Wei Hsu; Rong-Nan Chien; Sien-Sing Yang; Wei-Wen Su; Jaw-Ching Wu; Tzong-Hsi Lee; Cheng-Yuan Peng; Kuan-Chiao Tseng; Albert Qin; Yi-Wen Huang; Pei-Jer Chen
Journal:  JGH Open       Date:  2021-07-10

Review 8.  Hepatitis B virus-host interactions and novel targets for viral cure.

Authors:  Gaëtan Ligat; Eloi R Verrier; Michael Nassal; Thomas F Baumert
Journal:  Curr Opin Virol       Date:  2021-05-22       Impact factor: 7.121

Review 9.  Recent Advances in Hepatitis B Treatment.

Authors:  Georgia-Myrto Prifti; Dimitrios Moianos; Erofili Giannakopoulou; Vasiliki Pardali; John E Tavis; Grigoris Zoidis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01

Review 10.  A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.

Authors:  Wei Zhang; Mahmoud Aryan; Steve Qian; Roniel Cabrera; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.